P

Panaxia Labs Israel Ltd
TASE:PNAX

Watchlist Manager
Panaxia Labs Israel Ltd
TASE:PNAX
Watchlist
Price: 5 192 ILS -1.05% Market Closed
Market Cap: 7.9m ILS

Net Margin
Panaxia Labs Israel Ltd

-115%
Current
-81%
Average
5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-115%
=
Net Income
-30.3m
/
Revenue
26.4m

Net Margin Across Competitors

Panaxia Labs Israel Ltd
Glance View

Market Cap
7.9m ILS
Industry
Pharmaceuticals

Panaxia Labs Israel Ltd. engages in the manufacture and distribution of medical cannabis products. The firm provides pharma-grade smokeless cannabis products that provide better delivery systems for patients and physicians when properly assessing safety and dosage. Panaxia pharmaceutical cannabis products are specifically tailored to meet a broad range of needs. It's product portfolio includes: NAXIVA-PANAXOL Advanced kit for preparation of cannabis oil-standardized extract, NAXIVA-PANAXOL Purified extract for inhalation, PANAXIR Medical Cannabis Orodispersible Tablets, PANAXIR SENSE Orange Creamsicle Medical cannabis sublingual drops, PANAXIR CBD Melatonin Tablets, PANAXIR Medical cannabis extracts in ethanol among others.

PNAX Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-115%
=
Net Income
-30.3m
/
Revenue
26.4m
What is the Net Margin of Panaxia Labs Israel Ltd?

Based on Panaxia Labs Israel Ltd's most recent financial statements, the company has Net Margin of -115%.

Back to Top